IGI Logo

Aurobindo Pharma is currently trading at Rs. 1168.50, up by 15.80 points or 1.37 % from its previous closing of Rs. 1152.70 on the BSE.

The scrip opened at Rs. 1146.95 and has touched a high and low of Rs. 1168.90 and Rs. 1141.80 respectively. So far 19971 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1177.00 on 30-Jan-2024 and a 52 week low of Rs. 581.50 on 19-May-2023.

Last one week high and low of the scrip stood at Rs. 1175.60 and Rs. 1127.55 respectively. The current market cap of the company is Rs. 68261.85 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 41.30% and 6.87% respectively.

The United States Food and Drug Administration (USFDA) has concluded the inspection at Aurobindo Pharma’s wholly owned subsidiary-- Eugia Pharma Specialities’ Unit-II, a Formulation manufacturing facility, situated at Bhiwadi, Alwar, Rajasthan. USFDA had conducted an inspection from April 25, 2024 to May 3, 2024. The inspection closed with 7 observations. The observations are procedural in nature and will be responded to within the stipulated time. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.